Stockholm, Sweden – January 17, 2022 - iCellate Medical AB, a Swedish cancer diagnostics company, is happy to announce the 300 m2 expansion of its headquarters at Industrivägen in Solna just outside of Stockholm. The expansion comes as a natural next step in the company’s journey and allows for automation and scaling up of laboratory processes for the GeneMate® product.
Four years ago, iCellate moved from the area near The Karolinska Institute to Hagalund’s industrial park. Humlegården has been an accommodating landlord through the years, allowing for a smooth expansion of the company’s headquarters.
- The primary focus has been to increase lab space, but even additional office space and a new conference room have been included to support our growth, says Iohn Ryott who has spearheaded the expansion.
The expansion comes as a natural next step in response to an increase in demand for the company’s service GeneMate®, a test to identify an individual’s hereditary risk of developing cancer, as well as the launch of several clinical studies for CellMate®.
- We are very happy with how the new headquarters mirror the company’s growth. In order to sharpen GeneMate®’s competitive edge we need to automate our processes and increase volume. Both our R&D and operations teams are now much better equipped for continued development and scale, says Pelle Redare, iCellate’s CEO.
The expansion has been a stepwise process, beginning with new offices, a larger kitchen, and a large open concept workspace. The old office space was then reconfigured into new lab space. An important focus of the renovation has been working conditions in the lab, where new instruments require improved ventilation and cooling.
About iCellate Medical
iCellate is a spin-off of the Karolinska Institute in Sweden. The life-science company is headquartered in Solna where all its cancer diagnostic services are performed. iCellate has been the recipient of several awards and research grants from, among others, Roche, Eurostars, Vinnova, and Horizon 2020.
Stay up to date on iCellate's news via MyNewsDesk.